uh.. This OTAT meeting is see whether SI can demonstrate the appropriate potency assay and CMC items for Remestemcel in aGVHD not assessing the resubmission. FDA said once OTAT gives a tick for potency assay and CMC items then we can resub another BLA for aGVHD. FDA has also said the potency assay must be established before commencing another Phase 3 trial for Covid-19 ARDS. So yes you are correct this OTAT has nothing to do with ARDS but it's the potency assay and CMC items is.
Anyways, you are wrong that Novartis is only interested in Covid-19 ARDS. Don't forget Covid-19 ARDS is a form of ARDS which is a huge market worth billions. EUA under Covid-19 is the easiest way to obtain an approval and from there Mesoblast will conduct all cause ARDS trial. Now why would you gave up billions of dollar in potential revenue? Perhaps we couldn't address the potency assay? Who knows but all eyes are on OTAT meeting outcome. I just don't like the fact Novartis terminated the deal after OTAT meeting.
- Forums
- ASX - By Stock
- OTAT Meeting
uh.. This OTAT meeting is see whether SI can demonstrate the...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 32999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | 1.155 |
7 | 295447 | 1.150 |
3 | 70786 | 1.145 |
6 | 196386 | 1.140 |
3 | 75486 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 32999 | 1 |
1.170 | 62618 | 6 |
1.175 | 48590 | 3 |
1.180 | 79079 | 4 |
1.185 | 17090 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online